Ginkgo Bioworks Holdings Statistics
Total Valuation
DNA has a market cap or net worth of $470.04 million. The enterprise value is $431.04 million.
Important Dates
The next estimated earnings date is Tuesday, February 24, 2026, after market close.
| Earnings Date | Feb 24, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DNA has 56.84 million shares outstanding. The number of shares has increased by 7.58% in one year.
| Current Share Class | 45.32M |
| Shares Outstanding | 56.84M |
| Shares Change (YoY) | +7.58% |
| Shares Change (QoQ) | +1.41% |
| Owned by Insiders (%) | 16.96% |
| Owned by Institutions (%) | 53.55% |
| Float | 40.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.50 |
| Forward PS | 2.84 |
| PB Ratio | 0.84 |
| P/TBV Ratio | 0.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.39 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.39, with a Debt / Equity ratio of 0.76.
| Current Ratio | 4.39 |
| Quick Ratio | 4.20 |
| Debt / Equity | 0.76 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3,534.07 |
Financial Efficiency
Return on equity (ROE) is -50.02% and return on invested capital (ROIC) is -18.65%.
| Return on Equity (ROE) | -50.02% |
| Return on Assets (ROA) | -15.55% |
| Return on Invested Capital (ROIC) | -18.65% |
| Return on Capital Employed (ROCE) | -30.93% |
| Weighted Average Cost of Capital (WACC) | 6.76% |
| Revenue Per Employee | $216,554 |
| Profits Per Employee | -$407,129 |
| Employee Count | 834 |
| Asset Turnover | 0.14 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -519,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -35.64% in the last 52 weeks. The beta is 1.56, so DNA's price volatility has been higher than the market average.
| Beta (5Y) | 1.56 |
| 52-Week Price Change | -35.64% |
| 50-Day Moving Average | 9.07 |
| 200-Day Moving Average | 10.31 |
| Relative Strength Index (RSI) | 38.72 |
| Average Volume (20 Days) | 790,755 |
Short Selling Information
The latest short interest is 7.03 million, so 12.37% of the outstanding shares have been sold short.
| Short Interest | 7.03M |
| Short Previous Month | 6.49M |
| Short % of Shares Out | 12.37% |
| Short % of Float | 17.49% |
| Short Ratio (days to cover) | 7.33 |
Income Statement
In the last 12 months, DNA had revenue of $180.61 million and -$339.55 million in losses. Loss per share was -$6.21.
| Revenue | 180.61M |
| Gross Profit | 131.31M |
| Operating Income | -332.20M |
| Pretax Income | -340.07M |
| Net Income | -339.55M |
| EBITDA | -271.92M |
| EBIT | -332.20M |
| Loss Per Share | -$6.21 |
Full Income StatementBalance Sheet
The company has $461.86 million in cash and $422.87 million in debt, with a net cash position of $38.99 million or $0.69 per share.
| Cash & Cash Equivalents | 461.86M |
| Total Debt | 422.87M |
| Net Cash | 38.99M |
| Net Cash Per Share | $0.69 |
| Equity (Book Value) | 559.78M |
| Book Value Per Share | 9.85 |
| Working Capital | 390.80M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$165.82 million and capital expenditures -$21.37 million, giving a free cash flow of -$187.19 million.
| Operating Cash Flow | -165.82M |
| Capital Expenditures | -21.37M |
| Free Cash Flow | -187.19M |
| FCF Per Share | -$3.29 |
Full Cash Flow StatementMargins
Gross margin is 72.71%, with operating and profit margins of -183.94% and -188.00%.
| Gross Margin | 72.71% |
| Operating Margin | -183.94% |
| Pretax Margin | -188.29% |
| Profit Margin | -188.00% |
| EBITDA Margin | -150.56% |
| EBIT Margin | -183.94% |
| FCF Margin | n/a |
Dividends & Yields
DNA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.58% |
| Shareholder Yield | -7.58% |
| Earnings Yield | -72.24% |
| FCF Yield | -39.82% |
Analyst Forecast
The average price target for DNA is $10.50, which is 26.97% higher than the current price. The consensus rating is "Hold".
| Price Target | $10.50 |
| Price Target Difference | 26.97% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 20, 2024. It was a reverse split with a ratio of 1:40.
| Last Split Date | Aug 20, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:40 |
Scores
DNA has an Altman Z-Score of -7.01 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -7.01 |
| Piotroski F-Score | 2 |
